Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study
用户Ebm5_E91SfgE
1小时前
8
10
已完结
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2026-08-24 10:37:28 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规

